Longitudinal humoral immune response against COVID-19 adenovirus-based vaccines in patients with multiple sclerosis from Argentina undergoing immunosuppressive treatment

被引：0

作者：

Silva, B. A. ^{[1
,2
,3
]}

Miglietta, E. ^{[2
]}

Eizaguirre, B. ^{[1
]}

Alonso, R. ^{[1
]}

Wenker, S. ^{[2
]}

Casabona, J. C. ^{[2
]}

Casas, M. ^{[1
]}

Lazaro, L. ^{[1
]}

Cohen, L. ^{[1
]}

Pita, C. ^{[1
]}

Man, F. ^{[4
]}

Portuondo, G. ^{[4
]}

Bisso, A. Lopez ^{[4
]}

Zabala, N. ^{[4
]}

Casales, F. ^{[5
]}

Imhoff, G. ^{[6
]}

Steinberg, J. ^{[6
]}

Lopez, P. ^{[7
]}

Contentti, E. Carnero ^{[7
]}

Deri, N. ^{[8
]}

Sinay, V. ^{[9
]}

Hryb, J. ^{[10
]}

Chiganer, E. ^{[10
]}

Leguizamon, F. ^{[11
]}

Tkachuk, V. ^{[12
]}

Bauer, J. ^{[13
]}

Giachello, S. ^{[14
]}

Henestroza, P. ^{[14
]}

Garcea, O. ^{[1
]}

Vinzon, S. ^{[15
]}

Podhajcer, O. ^{[15
]}

Pitossi, F. ^{[2
]}

Ferrari, C. ^{[2
]}

机构：

[1] Hosp Ramos Mejia, Ctr Univ Esclerosis Multiple, Buenos Aires, Argentina

[2] Leloir Inst Fdn, Lab Terapias Regenerat Protectoras Sistema, Buenos Aires, Argentina

[3] Hosp Italiano Buenos Aires, Secc Enfermedades Desmielinizantes, Buenos Aires, DF, Argentina

[4] Hosp Ramos Mejia, Serv Neurol, Buenos Aires, DF, Argentina

[5] Sanatorio Arcos, Serv Neurol, Buenos Aires, Argentina

[6] Hosp Britanico, Serv Neuro, Buenos Aires, Argentina

[7] Hosp Aleman, Unidad Neuroinmunol, Buenos Aires, Argentina

[8] DIABAID, Buenos Aires, Argentina

[9] Fdn Favaloro, Buenos Aires, Argentina

[10] Hosp Durand, Consult Neuroinmunol Clin, Buenos Aires, Argentina

[11] Hosp Alvarez, Buenos Aires, Argentina

[12] Hosp Clin Buenos Aires, Clin Enfermedades Desmielinizantes, Buenos Aires, Argentina

[13] Esclerosis Multiple Argentina, Buenos Aires, Argentina

[14] Asociac Lucha Esclerosis Multiple, San Antonio, Argentina

[15] Leloir Inst Fdn, Lab Terapia Mol & Celular, Buenos Aires, Argentina

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1094

引用

页码：868 / 868

页数：1

共 50 条

[41] Evaluating Humoral Immune Response to mRNA COVID-19 Vaccines in Siponimod-treated Patients with Advancing Forms of Relapsing Multiple Sclerosis: A COVID-19 Vaccine Sub-study of Phase 3b EXCHANGE Trial
Bar-Or, A.
Mao-Draayer, Y.
Delgado, S. R.
Fox, R. J.
Cruz, L.
Meng, X.
Cox, G. Mavrikis
Cohan, S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 80 - 81
[42] Immune response against SARS-CoV-2 vaccines in treatment-naive multiple sclerosis patients
Ozakbas, S.
Baba, C.
Samadzade, U.
Kaya, E.
Ozcelik, S.
Ozdogar, A. T.
Dogan, Y.
Cevik, S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 776 - 776
[43] KINETICS OF HUMORAL IMMUNE RESPONSE IN PATIENTS WITH ASYMPTOMATIC OR MILD COVID-19: A LONGITUDINAL STUDY BASED IN AN IN-HOUSE INDIRECT ELISA METHOD
Silva, Nathanielly de Lima
Nobre, Danilo
de Oliveira, Joyceane Alves
Rezenda, Marcia Santos
da Conceicao dos Santos, Joyce Thayane
Marques Cavalcante, Rafael Ciro
de Souza Ferreira, Luiz Carlos
Cavalcante, Rafael Ciro Marques
Ferreira, Luiz Carlos de Souza
Martins-Filho, Paulo Ricardo
Schimieguel, Dulce Marta
EXCLI JOURNAL, 2022, 21 : 1167 - 1170
[44] Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection
Motwani, Kiran K.
Hashash, Jana G.
Farraye, Francis A.
Kappelman, Michael D.
Weaver, Kimberly N.
Zhang, Xian
Long, Millie D.
Cross, Raymond K.
JOURNAL OF CROHNS & COLITIS, 2023, 17 (10): : 1681 - 1688
[45] Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
Li, Xingxing
Wang, Ling
Liu, Jingjing
Fang, Enyue
Liu, Xiaohui
Peng, Qinhua
Zhang, Zelun
Li, Miao
Liu, Xinyu
Wu, Xiaohong
Zhao, Danhua
Yang, Lihong
Li, Jia
Cao, Shouchun
Huang, Yanqiu
Shi, Leitai
Xu, Hongshan
Wang, Yunpeng
Suo, Yue
Yue, Guangzhi
Nie, Jianhui
Huang, Weijin
Li, Wenjuan
Li, Yuhua
EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 1890 - 1899
[46] Comment on 'Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics'
Toplu, Sibel Altunisik
Altunisik, Nihal
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (04) : 394 - 394
[47] Humoral response to BNT162b2-COVID-19 or CoronaVac vaccine against COVID-19 in people with multiple sclerosis patients treated with high efficacy therapies
Galleguillos, L.
Alonso, R.
Kagi, M.
Hernandez, M.
Diaz, V.
Pallauta, K.
Jerez, M. E.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 792 - 792
[48] Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases
Troldborg, Anne
Thomsen, Marianne Kragh
Bartels, Lars Erik
Andersen, Jakob Bogh
Vils, Signe Risbol
Mistegaard, Clara Elbaek
Johannsen, Anders Dahl
Hermansen, Marie-Louise
Mikkelsen, Susan
Erikstrup, Christian
Hauge, Ellen-Margrethe
Ammitzboll, Christian
JOURNAL OF RHEUMATOLOGY, 2022, 49 (06) : 644 - 649
[49] Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Petereit, Hela-Felicitas
Tumani, Hayrettin
Zettl, Uwe K.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
[50] Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Piquet, Amanda L.
Corboy, John R.
Vollmer, Timothy L.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14

← 1 2 3 4 5 →